title: Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses.
abstract: Allergen-specific immunotherapy (SIT) involves the repeated administration of allergenic extracts to atopic individuals over a period of 3 to 5 years either subcutaneously (SCIT) or sublingually (SLIT) for the treatment of allergic respiratory diseases, including asthma and allergic rhinitis (AR). In studies, SCIT and SLIT have been shown to improve existing symptoms of asthma and AR and to also have the capability to cause disease-modifying changes of the underlying atopic condition so as to prevent new allergic sensitization as well as arrest progression of AR to asthma. Recent evidence suggests that immunotherapy brings about these effects through actions that use T-regulatory cells and blocking antibodies such as IgG(4) and IgA(2,) which can then result in an "immune deviation" from a T-helper (Th) 2 cell pattern to a Th1 cell pattern. Numerous meta-analyses and studies have been performed to evaluate the existing data among these studies, with the consensus recommendation favoring the use of immunotherapy because of its potential to modify existing diseases. Significant adverse reactions can occur with immunotherapy, including anaphylaxis and, very rarely, death. A primary factor in considering SIT is its potential to provide long-lasting effects that are able to be sustained well after its discontinuation. Given the significant burden these allergic diseases impose on the health-care system, SIT appears to be a cost-effective adjunctive treatment in modifying the existing disease state.
authors.affiliation: Division of Allergy, Pulmonary, and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.
authors.forename: Ravi K
authors.initials: RK
authors.lastname: Viswanathan
authors.affiliation: Division of Allergy, Pulmonary, and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI. Electronic address: wwb@medicine.wisc.edu.
authors.forename: William W
authors.initials: WW
authors.lastname: Busse
mesh_terms: D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage* / Q000276:immunology*; D003888:Desensitization, Immunologic / Q000009:adverse effects / Q000379:methods*; D000939:Epitopes / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D012130:Respiratory Hypersensitivity / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000485:Allergens; D000939:Epitopes